



SESSION 3

PROACTIVE/REACTIVE TDM Modern Use of TDM Across Agents

Niels Vande Castele, PharmD PhD

Therapeutic drug monitoring (TDM) is a tool that can be used to optimize biologic therapies in patients with inflammatory bowel disease. Not all patients require TDM, but in some it can provide substantial benefits to reach a therapeutic target. For new biologics that have come onto the market and which are less immunogenic, the focus has shifted from ruling out immunogenicity to confirming adequate drug exposure. Patients at risk of accelerated drug clearance—and therefore subtherapeutic drug exposure—can be identified as early as at initiation of therapy. The modern use of TDM across agents helps to identify those patients who have a lower likelihood of achieving a therapeutic target due to immune- or non-immune-mediated pharmacokinetic failure. Rapid lateral-flow based assays, together with dosing dashboards, now allow for precision dosing at point of care. The future of TDM is now, but will it live up to its promise?

References

- Assa A, Matar M, Turner D, et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring. *Gastroenterology*. 2019;157:985–96.e2.
- Dreesen E, Verstockt B, Bian S, et al. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2018;16:1937–46.e8.
- Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. *Gut*. 2020;69:1206–12.